1Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation[J]. Cell, 1990, 62∶999- 1006.
2Marian Aj, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy[J].J Mol Cell Cardiol,2001,33∶655-670.
3Spirito P, Seidman CE, McKenna WJ,et al. The management of hypertrophic cardiomyopathy[J]. N Engl J Med,1997,336∶775-785.
4Nishimura RA, Holmes DR. Hypertrophic Obstructive Cardiomyopathy[J]. N Engl J Med,2004,350∶1320-1327.
5Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade[J].Circulation, 1967,35∶847-851.
6Rosing DR, Kent KM, Borer JS, et al. Verapamil therapy: a new approach to pharmacologyic treatment of hypertrophic cardiomyopathy hemodynamic effects[J].Circulation,1979,60∶1201-1207.
7Wigle ED, Rakowski H, Kimball BP, et al.Hypertrophic cardiomyopathy: clinical spectrum and treatment[J].Circulation,1995, 92∶1680-1692.
8Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy[J].Circulation ,1981,64∶437-441.
10Adelman AG, Wigle ED, Ranganathan N, et al.The clinical course subaortic stenosis. A retrospective and prospective study of 60 hemodynamically proved cases[J]. Ann Intern Med, 1972, 77∶515-525.
1Guilbert JJ. The world health report 2006 : Working togeth-er for health [J]. Educ Health, 2006, 19: 385-387.
2Lorenzi M. The polyol pathway as a mechanism for diabeticretinopathy: attractive, elusive, and resilient [J]. Exp Di-abetes Res, 2007,2007 (:10): 1155-1165.
3Takei I, Kawai T, Tokui M,et al. Effects of cpalrcstat,an aldose reductase inhibitor, on diabetic peripheral neuropa-thy in patients with type 2 diabetes, in relation to suppres-sion of n (e) -carboxymethyl lysine [J]. J Diabetes Compli-cat, 2010, 24 (6): 424-432.
4Kyoko M, Yukinori S* Nobuya M, et al. Thirteen-month in-hibition of aldose reductase by zcnarcstat prevents morphologicalabnormalities in the dorsal root ganglia of streptozotocin-induceddiabetic rats [J]. Brain Res, 2009,1247: 182-187.
5Akihito F, Masuo K, Makoto M, et al. Stereospecific rec-ognition of a ,spirosuccinimi<de type aldose reductase inhibitor(as-3201 ) by plasma proteins: A significant role of specificbinding by serum albumin in the improved potcncy and stabil-ity [J]. Biochem Pharmacol, 2006,71 (3): 338-353.
6Rajarajcswart N, Pari L. Eflicacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabeticrats [J]. Chem Biol Interact, 2009,181 (3) : 292-296.
8Zelmanovitz T, Mello VD, Azevedo MJ, et al. Long-termeffect of a chicken-based diet versus enalapril on albuminuriain type 2 diabetic patients with microalbuminuria [J]. J RenNutr, 2008,IB (5): 440-447.
9Khamsch ME, Safarnejad B, Baradaran HR. The effect ofcaptopril on progression of retinopathy in type 2 diabetes[J]. Diabetes Technol Ther, 2009, 11 (11) : 711-715.
10Pamplona R, Portero-Otin M, Boada J, et al. Inhibitionof renin angiotensin system decreases renal protein oxidativedamage in diabetic rats [J]. Biochem Biophys Res Com-mun, 2008,368 (3): 528-535.
